Stockscreener 앱 받기
5.43
2.42%
0.1282
시간 외 거래:
5.43
전일 마감가:
$5.3018
열려 있는:
$5.35
하루 거래량:
2,690
Relative Volume:
0.37
시가총액:
$7.94M
수익:
-
순이익/손실:
$-16.49M
주가수익비율:
-0.1833
EPS:
-29.6295
순현금흐름:
$-15.24M
1주 성능:
+2.45%
1개월 성능:
-5.24%
6개월 성능:
+149.08%
1년 성능:
-45.70%
1일 변동 폭
$5.0821
$5.44
1주일 범위
$5.0821
$5.50
52주 변동 폭
$1.90
$10.59
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
명칭
Cns Pharmaceuticals Inc
전화
1-800-946-9185
주소
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.43 | 7.21M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 개시 | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
CNS Pharmaceuticals, Inc.Common Stock (NQ: CNSP - The Chronicle-Journal
CNS Pharmaceuticals (CNSP) Slips 2.81% to $5.54 as Shares Drift Toward Lower SupportSign of Weakness - dars.gov.et
CNS Pharmaceuticals Inc (CNSP) Stock Price, Quote, News & History - Benzinga
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company - globenewswire.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
CNS Pharmaceuticals (CNSP) Outlines Strategic Shift Amid Unprofi - GuruFocus
A biotech is seeking cancer or brain therapies. CNS Pharmaceuticals lays out its plan. - Stock Titan
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth - Yahoo Finance
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference - Weatherford Democrat
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa
Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com
CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan
CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan
Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn
Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan
CNSP Q2 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Shares Jump 7.18%Management Guidance Update - dars.gov.et
CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn
CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo
CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView
CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com
CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView
CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend RisesSlow Growth Warning - dars.gov.et
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus, Indivior Announce Merger to Create $2.2 Billion CNS - Voice of Healthcare
Supernus Pharmaceuticals and Indivior Pharmaceuticals to - GlobeNewswire
CNS Pharmaceuticals Inc (CNSP) Cash Flow - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.230|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.070|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNS Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CNSP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech - Mugglehead Investment Magazine
CNSP Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesAnalyst Coverage Count - careplusvn.com
CNSP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Drug Developer Navigates Clinical MilestonesPerformance Review - dars.gov.et
CNS Pharmaceuticals(CNSP) Stock Options Chain | Quotes & News - Moomoo
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Costs PersistShare Repurchase Impact - DonanımHaber
CNS Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical Milestones - dars.gov.et
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Cns Pharmaceuticals Inc (CNSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cns Pharmaceuticals Inc 주식 (CNSP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Charles Faith L. | Director |
May 18 '26 |
Buy |
4.79 |
7,100 |
34,002 |
7,100 |
0.50%
0.57%
자본화:
|
볼륨(24시간):